| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7265221 | PFIZER | Pyrrolo[2,3-d]pyrimidine compounds |
Dec, 2020
(3 years ago) | |
| US7301023 | PFIZER | Chiral salt resolution |
Dec, 2020
(3 years ago) | |
| US6965027 | PFIZER | Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate |
Mar, 2023
(1 year, 1 month ago) | |
| US6956027 | PFIZER | N-terminally chemically modified protein compositions and methods |
Mar, 2023
(1 year, 1 month ago) | |
| USRE41783 | PFIZER | Pyrrolo[2,3-D]pyrimidine compounds |
Dec, 2025
(1 year, 7 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7842699 | PFIZER | Pyrrolo[2,3-D]pyrimidine compounds |
Dec, 2020
(3 years ago) | |
| US6956041 | PFIZER | Pyrrolo[2,3-d]pyrimidine compounds |
Dec, 2020
(3 years ago) | |
| US7091208 | PFIZER | Pyrrolo[2,3-D]pyrimidine compounds |
Dec, 2020
(3 years ago) | |
| US9937181 | PFIZER | Tofacitinib oral sustained release dosage forms |
Mar, 2034
(9 years from now) | |
| US11253523 | PFIZER | Tofacitinib oral sustained release dosage forms |
Mar, 2034
(9 years from now) | |
| US10639309 | PFIZER | Tofacitinib oral sustained release dosage forms |
Mar, 2034
(9 years from now) | |
Xeljanz Xr is owned by Pfizer.
Xeljanz Xr contains Tofacitinib Citrate.
Xeljanz Xr has a total of 11 drug patents out of which 7 drug patents have expired.
Expired drug patents of Xeljanz Xr are:
- US7842699
- US6956041
- US7091208
- US7265221
- US7301023
- US6965027
- US6956027
Xeljanz Xr was authorised for market use on 23 February, 2016.
Xeljanz Xr is available in tablet, extended release;oral dosage forms.
Xeljanz Xr can be used as treatment of adult patients with moderately to severely active ulcerative colitis (uc), treatment of rheumatoid arthritis, a method of treating ulcerative colitis, by administering the formulation of tofacitinib of claims 1, 3, 8, 10, 15-20, 22, 27-31, 34-43, 50, 52, 59, 61, 68-71, 73, 75, 82-84 and 87-98.
Drug patent challenges can be filed against Xeljanz Xr from 06 November, 2016.
The generics of Xeljanz Xr are possible to be released after 14 March, 2034.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-879) | Dec 14, 2024 |
| New Indication(I-761) | Dec 14, 2020 |
| New Chemical Entity Exclusivity(NCE) | Nov 06, 2017 |
Drugs and Companies using TOFACITINIB CITRATE ingredient
NCE-1 date: 06 November, 2016
Market Authorisation Date: 23 February, 2016
Treatment: Treatment of adult patients with moderately to severely active ulcerative colitis (uc); Treatment of rheumatoid arthritis; A method of treating ulcerative colitis, by administering the formulation of ...
Dosage: TABLET, EXTENDED RELEASE;ORAL
XELJANZ XR family patents
